News | Colonoscopy Systems | April 15, 2019

Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening

Pilot study of preparation-free ingestible capsule will enroll up to 45 patients at average risk for polyps and colon cancer

Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening

April 15, 2019 — Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through detection of precancerous polyps, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested C-Scan, a preparation-free capsule, at the New York University School of Medicine.

"We are pleased to participate in this pilot study of C-Scan, a preparation-free capsule-based system for the prevention of colorectal cancer being tested in the U.S.," noted Seth A. Gross, M.D., gastroenterologist and associate professor of medicine, NYU Langone Health. "Unfortunately, colorectal cancer remains the second-leading cause of cancer death in the U.S. But we know that with the utilization of colorectal cancer screening, we can reduce the incidence and mortality rates related to this disease. The potential addition of a new screening option that is capsule-based and does not require a bowel prep offers the promise of increasing our screening rates. We are looking to the results of this study and the potential for an effective new screening option for the prevention and early detection of colorectal cancer."

The single-arm pilot study (NCT03735407) will enroll up to 45 subjects considered to be of average risk for polyps and colon cancer. The study is evaluating the safety, usability and subject compliance of the C-Scan system.

It is estimated that in 2018, there were approximately 881,000 deaths and more than 1.8 million new cases of colorectal cancer (CRC) worldwide. CRC typically begins as precancerous polyps or abnormal growths in the colon or rectum, which can be present for up to 10 years before developing into invasive cancer. As a result, screening for precancerous polyps is the most direct method for CRC prevention. Despite evidence that standard screening can prevent CRC, adherence remains low due to the required bowel preparation, invasiveness, and in some communities, limited access.

The C-Scan system utilizes an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3-D map of the inner lining of the colon. C-Scan is non-invasive and requires no preparation or sedation, allowing the patient to continue their daily routine with no interruption as the capsule is propelled through the gastrointestinal tract by natural motility.

Read the article "Check-Cap Enrolls First Patient in C-Scan Colorectal Cancer Screening Clinical Trial"

For more information: www.check-cap.com

Related Content

An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
A cutting-edge magnet resonance imaging (MRI) technique to detect iron deposits in different brain regions can track declines in thinking, memory and movement in people with Parkinson's disease #Parkinsons #MRI

Summary steps of the processing pipeline for QSM reconstruction (phase pre-processing and map estimation) and whole brain/regional analysis. ANTs, advanced normalisation tools; MP-RAGE, magnetisation-prepared, 3D, rapid, gradient-echo; MSDI, multi-scale dipole inversion; QSM, quantitative susceptibility mapping; ROI, region of interest; SWI, susceptibility weighted imaging.

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — A cutting-edge...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
aycan completed the install of a second aycan xray-print solution at Inspira Health in New Jersey
News | X-Ray | February 10, 2020
February 10, 2020 — aycan completed the install of a second...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
News | Clinical Trials | February 03, 2020
February 3, 2020 — Melding the genetic and cellular analysis of tumors with how they appear in medical images could g
Automated Triage of Thyroid Cancer

73-year-old man with papillary carcinoma of left lobe of thyroid. Screen shot shows example of thyroid nodule annotation (segmentation and TI-RADS annotation) performed on ultrasound image in longitudinal projection with electronic Physician Annotation Device software (Stanford Medicine Radiology). Radiologists performed nodule segmentation by selecting points (red) on nodule outline (green), while controlling smoothing of outline polygon by means of spline interpolation.

News | Ultrasound Imaging | January 30, 2020
January 30, 2020 — According to an ar...
Rayence C-Series wireless DR detector

Image courtesy of Rayence

News | Digital Radiography (DR) | January 27, 2020
January 27, 2020 — The expansion of med...
Medical imaging technology company Oxipit announced partnership with Swiss medical distribution company Healthcare Konnect to bring ChestEye AI imaging suite to healthcare institutions in Nigeria
News | Artificial Intelligence | January 22, 2020
January 22, 2020 — Medical imaging technology company Oxipit ann
Virtual reality during chemotherapy has been shown to improve breast cancer patients’ quality of life during the most stressful treatments
News | Virtual and Augmented Reality | January 21, 2020
January 21, 2020 — Virtual reality during chemotherapy has been shown to improve...